First human test of new cell therapy for inherited nerve disease
NCT ID NCT06328712
Summary
This was a very early, small study to check the safety of a new cell therapy called EN001 for people with Charcot-Marie-Tooth disease type 1A (CMT1A), a genetic nerve disorder. Six adult participants received two doses of EN001 to find the highest safe amount. Researchers monitored them closely for side effects and also looked for any early signs that the treatment might help with symptoms like muscle weakness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHARCOT-MARIE-TOOTH DISEASE TYPE 1A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.